CRISPR-Cas12-based detection of SARS-CoV-2

An outbreak of betacoronavirus severe acute respiratory syndrome (SARS)-CoV-2 began in Wuhan, China in December 2019. COVID-19, the disease associated with SARS-CoV-2 infection, rapidly spread to produce a global pandemic. We report development of a rapid (<40 min), easy-to-implement and accurate...

Full description

Saved in:
Bibliographic Details
Published in:Nature biotechnology Vol. 38; no. 7; pp. 870 - 874
Main Authors: Broughton, James P, Deng, Xianding, Yu, Guixia, Fasching, Clare L, Servellita, Venice, Singh, Jasmeet, Miao, Xin, Streithorst, Jessica A, Granados, Andrea, Sotomayor-Gonzalez, Alicia, Zorn, Kelsey, Gopez, Allan, Hsu, Elaine, Gu, Wei, Miller, Steve, Pan, Chao-Yang, Guevara, Hugo, Wadford, Debra A, Chen, Janice S, Chiu, Charles Y
Format: Journal Article
Language:English
Published: United States Nature Publishing Group 01.07.2020
Subjects:
Assaying
Betacoronavirus - genetics
Betacoronavirus - isolation & purification
Clinical Laboratory Techniques
Coronavirus Infections - diagnosis
Coronavirus Infections - virology
Coronaviruses
COVID-19
COVID-19 Testing
COVID-19 Vaccines
CRISPR
CRISPR-Cas Systems
Disease control
Humans
Nucleic Acid Amplification Techniques - methods
Pandemics
Pneumonia, Viral - diagnosis
Pneumonia, Viral - virology
Respiratory diseases
Ribonucleic acid
RNA
RNA, Guide, CRISPR-Cas Systems - genetics
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Time Factors
Viral diseases
United States > US
ISSN:1087-0156, 1546-1696, 1546-1696
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An outbreak of betacoronavirus severe acute respiratory syndrome (SARS)-CoV-2 began in Wuhan, China in December 2019. COVID-19, the disease associated with SARS-CoV-2 infection, rapidly spread to produce a global pandemic. We report development of a rapid (<40 min), easy-to-implement and accurate CRISPR-Cas12-based lateral flow assay for detection of SARS-CoV-2 from respiratory swab RNA extracts. We validated our method using contrived reference samples and clinical samples from patients in the United States, including 36 patients with COVID-19 infection and 42 patients with other viral respiratory infections. Our CRISPR-based DETECTR assay provides a visual and faster alternative to the US Centers for Disease Control and Prevention SARS-CoV-2 real-time RT-PCR assay, with 95% positive predictive agreement and 100% negative predictive agreement.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1087-0156
1546-1696
1546-1696
DOI:10.1038/s41587-020-0513-4